|
<PAGE>
Exhibit 10.1
AMENDMENT TO THE
DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT
BETWEEN
WYETH, ACTING THROUGH ITS WYETH CONSUMER HEALTHCARE
DIVISION,
AND
IMPAX LABORATORIES, INC.
This Amendment, effective as of February 14, 2005 (the
"Effective
Date"), to the Development, License and Supply Agreement, dated
as of June 1,
2002 and amended by letters dated November 19, 2002, April 23,
2003 and May 15,
2003 and amendment dated July 9, 2004, for
Loratadine/Pseudoephedrine
Combination Tablets (the "Agreement") is entered into by and
between Wyeth,
acting through its Wyeth Consumer Healthcare Division
(hereinafter called
"WCH"), and Impax Laboratories, Inc. (hereinafter called
"IMPAX").
PURPOSE
WHEREAS, under the Agreement, IMPAX has agreed to supply WCH
with D-24
Product (as defined in the Agreement);
WHEREAS, IMPAX and WCH wish to terminate the Agreement with
respect to
the D-24 Product only, all in accordance with the terms and
subject to the
conditions set forth in this Amendment.
NOW, THEREFORE, in consideration of the foregoing premises and
the
mutual covenants contained herein and intending to be legally
bound hereby, the
parties hereby agree as follows:
1. Unless otherwise expressly defined herein, all capitalized
terms
used herein shall have the same meaning as defined
| 
